- Organizations: OKYO Pharma
Business
Leadership watch: OKYO, Orbis, and BVI Medical name new CEOs
Leadership changes are underway in the eyecare space—and we’ve got the latest.
Pipeline
OKYO Pharma reports favorable phase 2 data for NCP asset
Formerly OK-101, urcosimod is formulated for topical application, with latest results demonstrating a favorable impact on corneal nerve health.
Pipeline
FDA grants Fast Track designation to OKYO Pharma's NCP therapeutic
New status gives urcosimod an expedited pathway toward potential market approval as first approved treatment for this patient base.
Pipeline
OKYO's urcosimod demonstrates long-term stability for NCP
With a real-world study ongoing, urcosimod’s +2.5-year shelf stability further supports a potential NDA submission for regulatory approval down the road.Pipeline
OKYO Pharma seeks Fast Track designation for NCP candidate
Designation would give urcosimod (formerly OK-101) an expedited pathway to potentially become the first approved treatment for this orphan disease.
Pipeline
FDA approves Okyo Pharma's IND for neuropathic corneal pain candidate
Acceptance paves the way for phase 2 trial on OK-101, with the goal to become first FDA-approved therapy for this condition.
Pipeline
OKYO Pharma submits IND for neuropathic corneal pain treatment
Pending FDA acceptance, phase 2 clinical trial is planned to commence in Q1 2024.
Pipeline
Okyo Pharma to launch real-world trial on OK-101 for NCP
Phase 2 study is planned as part of partnership with Tufts Medical Center; follows ongoing first-in-human study of OK-101 for DED.
Pipeline